BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36041543)

  • 1. A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer.
    Wester L; Venneker S; Hazenoot M; Pont C; Koedoot E; Timmermans AM; Martens JWM; Jansen MPHM; Kockx CEM; van IJcken WFJ; Meerman JHN; Zhang Y; van de Water B
    Biochem Pharmacol; 2022 Oct; 204():115233. PubMed ID: 36041543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
    Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
    Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.
    Zhang Y; Wester L; He J; Geiger T; Moerkens M; Siddappa R; Helmijr JA; Timmermans MM; Look MP; van Deurzen CHM; Martens JWM; Pont C; de Graauw M; Danen EHJ; Berns EMJJ; Meerman JHN; Jansen MPHM; van de Water B
    Oncogene; 2018 Apr; 37(14):1869-1884. PubMed ID: 29353882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
    Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines.
    van Agthoven T; Godinho MF; Wulfkuhle JD; Petricoin EF; Dorssers LC
    Int J Cancer; 2012 Nov; 131(9):1998-2007. PubMed ID: 22328489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim.
    Periyasamy-Thandavan S; Takhar S; Singer A; Dohn MR; Jackson WH; Welborn AE; LeRoith D; Marrero M; Thangaraju M; Huang S; Schoenlein PV
    Breast Cancer Res; 2012 Mar; 14(2):R52. PubMed ID: 22429491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
    Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
    Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of the EGFR/MEK1/MAPK1/2 signaling axis as a mechanism of resistance to antiestrogen‑induced BimEL dependent apoptosis in ER
    Hagan ML; Mander S; Joseph C; McGrath M; Barrett A; Lewis A; Hill WD; Browning D; McGee-Lawrence ME; Cai H; Liu K; Barrett JT; Gewirtz DA; Thangaraju M; Schoenlein PV
    Int J Oncol; 2023 Feb; 62(2):. PubMed ID: 36524361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
    Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
    Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
    Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
    BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
    Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
    Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.
    Bobustuc GC; Smith JS; Maddipatla S; Jeudy S; Limaye A; Isley B; Caparas ML; Constantino SM; Shah N; Baker CH; Srivenugopal KS; Baidas S; Konduri SD
    Mol Med; 2012 Sep; 18(1):913-29. PubMed ID: 22549111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
    Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
    Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.